1st Oct 2014 11:46
LONDON (Alliance News) - Isis Pharmaceuticals Inc announced that it has earned a USD1.5 million milestone payment from GlaxoSmithKline PLC related to the advancement of the programme to develop ISIS-GSK4Rx to treat an undisclosed ocular disease.
"Our collaboration with Glaxo has been very productive resulting in four drugs in development. We look forward to advancing ISIS-GSK4Rx into clinical development and providing more information on the target and disease opportunity, which we are very excited about," said Lynne Parshall, chief operating officer at Isis.
Copyright RTT News/dpa-AFX
Related Shares:
Glaxosmithkline